1630GCC: A Pilot Study of Zydelig in Patients With B-cell Malignancies as Post-Autologous Transplant Remission Maintenance
Phase of Trial: Phase II
Latest Information Update: 07 Nov 2019
Price : $35 *
At a glance
- Drugs Idelalisib (Primary)
- Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- 30 Jan 2018 Status changed from not yet recruiting to recruiting.
- 07 Sep 2017 Planned initiation date changed from 1 Jun 2017 to 1 Oct 2017.
- 04 May 2017 New trial record